This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Antibody Drugs Medicine 
Bio Pharma Dive
DECEMBER 8, 2022
As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.
334 
Bio Pharma Dive
SEPTEMBER 21, 2021
Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019.
297
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MAY 18, 2021
The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.
340 
Bio Pharma Dive
NOVEMBER 14, 2024
The company is paying China-based biotech LaNova Medicines $588 million for the type of dual-pronged antibody drug that recently bested Keytruda in a clinical trial.
316 
Bio Pharma Dive
OCTOBER 26, 2022
The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease. It joins a group of medicines on market that target a protein called BCMA.
302 
Bio Pharma Dive
MARCH 23, 2023
The two companies gained billions of dollars in market value after their antibody drug succeeded against a disease that’s been difficult to treat with biologic medicines.
298 
Bio Pharma Dive
JULY 14, 2023
billion to acquire the private biotech and its experimental antibody, which Lilly plans to pair with its own weight loss medicines. The pharma will pay up to $1.9
246 
Bio Pharma Dive
JANUARY 8, 2024
The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.
200 
Pharmaceutical Technology
AUGUST 18, 2022
Atomwise and Sanofi have entered a strategic and exclusive research partnership to use the former’s artificial intelligence (AI)-driven AtomNet platform to discover and research up to five drug targets computationally. The post Atomwise and Sanofi partner for drug discovery using AI appeared first on Pharmaceutical Technology.
246 
XTalks
JANUARY 21, 2025
The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca.
105 
Bio Pharma Dive
APRIL 14, 2023
Newly launched TORL BioTherapeutics wants to develop a variety of antibody drugs, and comes equipped with $158 million as well as a close partnership with the lab of pioneering breast cancer researcher Dennis Sloman.
189 
Bio Pharma Dive
MARCH 29, 2022
The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines.
130 
Bio Pharma Dive
JUNE 21, 2024
A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.
173 
Pharmaceutical Technology
DECEMBER 26, 2022
LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The post LegoChem, Amgen partner to develop antibody drug conjugates appeared first on Pharmaceutical Technology.
130 
Bio Pharma Dive
SEPTEMBER 16, 2022
If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants.
195 
Pharma Mirror
APRIL 18, 2023
Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
130 
Pharmaceutical Technology
JANUARY 23, 2023
Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis. development and commercial milestones.
130 
STAT News
NOVEMBER 30, 2022
The Food and Drug Administration on Wednesday ended its emergency authorization for the only remaining Covid-19 antibody therapy cleared for use, saying variants that render it ineffective are now dominant in the United States. have been growing in prevalence. Read the rest…
111 
Pharmaceutical Technology
MARCH 9, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.
147 
XTalks
FEBRUARY 21, 2025
Antibody-drug conjugates (ADCs) have emerged as one of the most promising advancements in precision oncology, combining targeted delivery with the potency of traditional chemotherapies. Over the last decade, ADCs have gained significant traction, with more therapies being approved and a rapidly expanding development pipeline.
52 
pharmaphorum
MAY 30, 2022
pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advancing through precision medicine and targeted therapies. That antibody-drug conjugate then docks on the cancer cell receptor.
116 
Pharmaceutical Technology
JANUARY 4, 2023
The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has granted clearance for Transcenta’s investigational new drug (IND) application for its TST003 to treat solid tumours. TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody.
242 
Pharmaceutical Technology
NOVEMBER 27, 2022
Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.
130 
Bio Pharma Dive
APRIL 3, 2024
The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.
189 
Pharmaceutical Technology
FEBRUARY 17, 2023
In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The focus on identifying the ideal drug dosage is not new. What is drug dose optimisation?
289 
Pharmaceutical Technology
APRIL 13, 2023
Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.
130 
Bio Pharma Dive
NOVEMBER 30, 2023
The acquisition of ImmunoGen gives AbbVie an approved medicine for ovarian cancer, and continues a pharma spending spree on antibody-drug conjugates.
173 
Pharmaceutical Technology
MAY 8, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Monoclonal antibody conjugates for cancer treatment.
130 
Bio Pharma Dive
JUNE 28, 2023
The companies aim to seek an FDA nod for their bispecific antibody, Epkinly, in follicular lymphoma, where it would compete with a recently approved Roche medicine.
162 
Pharmaceutical Technology
APRIL 3, 2023
Hyrimoz has been approved for use in all the indications covered by the reference medicine Humira, including plaque psoriasis, rheumatic diseases, ulcerative colitis, Crohn’s disease, uveitis and hidradenitis suppurativa. Its reference medicine, Humira, initially received approval with an adalimumab 50 mg/mL concentration.
264 
Pharmaceutical Technology
NOVEMBER 25, 2022
An antibody-drug conjugate (ADC), Enhertu comprises a HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a stable tetrapeptide-based cleavable linker. Nausea, fatigue, vomiting, reduced neutrophil count, alopecia and anaemia among others were observed to be the most prevalent adverse reactions.
263 
Pharmaceutical Technology
OCTOBER 7, 2022
Provention Bio and Sanofi US have signed a co-promotion agreement to launch the former’s lead investigational drug candidate, teplizumab for the delay in the onset of clinical type 1 diabetes (T1D). The US Food and Drug Administration (FDA) is presently reviewing teplizumab for the delay of clinical T1D in people who are at risk.
299 
Pharmaceutical Technology
APRIL 5, 2023
Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.
130 
pharmaphorum
OCTOBER 28, 2020
The US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million if the drug gets Emergency Use Authorisation (EUA) – although its effectiveness has been called into question. Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter where they live.
104 
XTalks
DECEMBER 4, 2024
In this episode, Ayesha spoke with John Yu, MD, CEO of Kairos Pharma , a company advancing therapies to overcome challenges in cancer drug resistance and immune suppression. Kairos is developing therapeutics that reverse cancer drug resistance in cancers such as prostate and lung cancer. Dr. Yu has also led numerous clinical trials.
59 
Pharmaceutical Technology
APRIL 6, 2023
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted ADvantage Therapeutics’ immunotherapy AD04 an Innovation Passport for the treatment of Alzheimer’s disease. The difficulty in finding a treatment for Alzheimer’s disease has plagued the drug industry for decades.
264 
Medical Xpress
NOVEMBER 9, 2022
A new approach to stem cell therapy that uses antibodies instead of traditional immunosuppressant drugs robustly preserves cells in mouse brains and has potential to fast-track trials in humans, a Michigan Medicine study suggests.
98 
Pharmaceutical Technology
APRIL 17, 2023
Pharmaceutical company Genmab is entering a partnership with argenx to develop antibody therapies for oncology and immunology. This collaboration is being made to combine the companies’ capabilities to develop novel therapeutic antibodies with applications in the two disease areas.
130 
pharmaphorum
MARCH 24, 2022
GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. The post GSK partners LifeMine on fungi-derived medicines appeared first on.
105 
Pharmaceutical Technology
AUGUST 16, 2022
Gilead Sciences has entered an agreement with Everest Medicines to acquire complete rights to develop and market Trodelvy (sacituzumab govitecan) in Greater China, Singapore, South Korea, Philippines, Vietnam, Thailand, Indonesia, Mongolia and Malaysia. Gilead will also have a chance to hire Everest staff working on the Trodelvy programme.
255
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content